Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Concomitant use of temozolomide (TMZ) and radiotherapy, which is the standard therapy for patients with high-grade glioma, involves a unique regimen with multiple-day, long-term administration. In a previous study, we showed not only higher incidence rates of chemotherapy-induced nausea and vomiting (CINV) during the overall study period, but also substantially higher incidence rates of moderate/severe nausea and particularly severe appetite suppression during the late phase of the treatment. Here, we prospectively evaluated the efficacy of a combination of palonosetron, aprepitant, and dexamethasone for CINV in patients treated with concomitant TMZ and radiotherapy. Twenty-one consecutive patients with newly diagnosed high-grade glioma were enrolled. CINV was recorded using a daily diary and included nausea assessment, emetic episodes, degree of appetite suppression, and use of antiemetic medication. The percentage of patients with a complete response in the overall period was 76.2%. The percentages of patients with no moderate/severe nausea were 90.5, 100, and 90.5% in the early phase, late phase, and overall period, respectively. Severe appetite suppression throughout the overall period completely disappeared. The combination of palonosetron, aprepitant, and dexamethasone was highly effective and well tolerated in patients treated with concomitant TMZ and radiotherapy. This combination of antiemetic therapy focused on delayed as well as acute CINV and may have the potential to overcome CINV associated with a multiple-day, long-term chemotherapy regimen.
Department of Neurosurgery, Faculty of Medicine, University of Tsukuba.
Masahide
M
Matsuda
Tetsuya
T
Yamamoto
Eiichi
E
Ishikawa
Hiroyoshi
H
Akutsu
Shingo
S
Takano
Akira
A
Matsumura
D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D000077608:Aprepitant; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives*; D003907:Dexamethasone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005910:Glioma / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D000077924:Palonosetron; D011446:Prospective Studies; D011812:Quinuclidines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use; D000077204:Temozolomide; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000932:Antiemetics; D018906:Antineoplastic Agents, Alkylating; D007546:Isoquinolines; D009025:Morpholines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D000077608:Aprepitant; D000077924:Palonosetron; D003606:Dacarbazine; D003907:Dexamethasone; D000077204:Temozolomide
Support Care Cancer. 2011 Jun;19(6):823-32
20495832
J Natl Compr Canc Netw. 2007 Jan;5(1):51-9
17239326
Cancer Manag Res. 2014 Sep 05;6:329-37
25228819
J Clin Oncol. 2011 Nov 1;29(31):4189-98
21947834
Ann Oncol. 2011 Apr;22(4):939-46
20935058
Eur J Pharmacol. 2012 Aug 15;689(1-3):25-30
22683863
Ann Oncol. 2010 May;21 Suppl 5:v232-43
20555089
Lancet Oncol. 2009 Feb;10(2):115-24
19135415
N Engl J Med. 2010 Mar 11;362(10):865-9
20220181
Neurol Med Chir (Tokyo). 2010;50(8):638-44
20805645
Neurol Med Chir (Tokyo). 2015;55(9):749-55
26345664
Neurosurg Rev. 2010 Oct;33(4):441-9
20706757
Br J Radiol. 2011 Dec;84 Spec No 1:S54-60
21427185
Cancer. 2003 Jun 15;97(12):3090-8
12784346
Cancer. 2010 Dec 15;116(24):5659-66
21218459
N Engl J Med. 2005 Mar 10;352(10 ):987-96
15758009